Table 1.
Patient demographics of Group 1 & 2.
| Group 1 & 2 (N = 30) | Group 1 (N = 16) | Group 2 (N = 14) | P-value | |
|---|---|---|---|---|
| Age at diagnosis of CNV (years) (range) | 50.6 ± 10.1 (30–74) | 51.7 ± 8.2 (39–67) | 49.3 ± 12.2 (30–74) | 0.61* |
| Gender (male: female) | 23: 7 (3.3: 1) | 11:5 (2.2:1) | 12:2 (6:1) | 0.26† |
| Mean duration of follow-up (months) (range) | 60.0 ± 53.4 (2.2–145.2) | 77.3 ± 54.7 (9.3–145.2) | 37.0 ± 42.0 (2.2–135.9) | 0.02* |
| Systemic disease | ||||
| Diabetes mellitus, n (%) | 4 (13.3) | 2 (12.5) | 2 (14.3) | 0.65† |
| Hypertension, n (%) | 10 (33.3) | 7 (43.8) | 3 (21.4) | 0.18† |
| Treated eye (Right: Left) | 13:17 | 5:11 | 8:6 | 0.15† |
| Duration from diagnosis of CSC to development of secondary CNV in Group 1 (months) (median) [range] | N. A. | 50.6 ± 50.3 (40.5) [0.6–156.0] |
N. A. | |
| LogMAR BCVA at diagnosis of CNV | 0.54 ± 0.50 | 0.48 ± 0.52 | 0.61 ± 0.49 | 0.28* |
CNV = choroidal neovascularization; BCVA = best corrected visual acuity; N. A. = not applicable; logMAR = logarithm of minimal angle of resolution.
Group 1: Patients with secondary CNV in eyes with previous CSC.
Group 2: Patients diagnosed with CNV in eyes with putative chronic CSC beforehand.
*Statistical analysis with Mann-Whitney U tests between Group 1 & 2.
†Statistical analysis with Fisher’s exact tests between Group 1 & 2.